What Is the Core Difference?
Tirzepatide and Retatrutide are both synthetic incretin peptides, but they target different combinations of receptors. Tirzepatide (LY3298176) is a dual agonist of GLP-1 and GIP receptors. Retatrutide (LY3437943) is a triple agonist adding Glucagon receptor activation to the same two targets.
That single additional receptor — the glucagon receptor — is what makes Retatrutide mechanistically distinct. Glucagon receptor activation drives thermogenesis and increases hepatic energy expenditure, adding a fat-burning mechanism that neither GLP-1 nor GIP agonism provides. The hypothesis underlying Retatrutide research is that this extra metabolic lever, combined with GLP-1 and GIP agonism, could produce additive weight reduction beyond what dual agonism achieves.
For researchers, the question is whether that hypothesis holds in clinical data — and what the Phase 2 results actually showed compared to Tirzepatide's SURMOUNT programme.
Receptor Target Comparison
| Property | Tirzepatide | Retatrutide |
|---|---|---|
| INN / Code | LY3298176 | LY3437943 |
| GLP-1R | ✓ Agonist | ✓ Agonist |
| GIPR | ✓ Agonist | ✓ Agonist |
| Glucagon R | — Not targeted | ✓ Agonist |
| Class | Dual incretin agonist | Triple incretin agonist |
| Developer | Eli Lilly | Eli Lilly |
| Half-life | ~5–7 days | ~6 days (est.) |
| Clinical Phase | Approved (Phase 4 ongoing) | Phase 3 (TRIUMPH programme) |
What Does the Clinical Data Show?
Directly comparing the two compounds requires care: their Phase 2 and Phase 3 programmes used different populations, protocols, and timeframes. That said, the headline numbers are frequently discussed in the research literature and are worth examining.
Tirzepatide — SURMOUNT-1 (NEJM, 2022): At 15mg/week over 72 weeks in adults with obesity (no diabetes), mean body weight reduction was 20.9%. This was the benchmark result that established Tirzepatide as the highest-performing approved compound at the time.
Retatrutide — Phase 2 (NEJM, 2023): At 12mg/week over 48 weeks, mean body weight reduction reached 24.2% — higher than SURMOUNT-1, though over a shorter trial period and in a Phase 2 (not Phase 3) context. At lower doses (4mg and 8mg), Retatrutide showed dose-dependent responses of approximately 8.7% and 17.3% respectively.
The 48-week vs 72-week difference matters: weight loss trajectories with GLP-1 class compounds typically plateau between weeks 40–60, meaning a 48-week observation may not capture the full extent of reduction. Phase 3 TRIUMPH data will be the definitive comparison point.
The Glucagon Receptor: What It Adds
The glucagon receptor is central to understanding why researchers are interested in Retatrutide beyond the weight outcome numbers. Glucagon receptor agonism has two primary metabolic effects:
- Increased hepatic energy expenditure — glucagon drives glycogenolysis and gluconeogenesis in the liver, increasing metabolic rate independent of food intake
- Thermogenesis — glucagon receptor activation promotes brown adipose tissue activity, increasing non-shivering thermogenesis and caloric expenditure at rest
These thermogenic effects distinguish Retatrutide from purely appetite-suppressive compounds. While GLP-1 and GIP agonism primarily reduce caloric input, glucagon receptor co-activation increases energy output simultaneously — a dual-sided metabolic intervention.
The trade-off is that isolated glucagon receptor agonism raises blood glucose (the opposite of GLP-1's effect). Retatrutide's design balances this by co-activating GLP-1 to provide the necessary insulin secretion offset. This receptor balancing act is a key area of ongoing research interest.
Research Considerations: Which to Choose?
For Australian researchers selecting between the two compounds, the decision typically turns on the research question:
- Studying dual incretin pathways, GLP-1/GIP synergy, or protocols aligned with approved therapies — Tirzepatide has a larger published evidence base, four completed SURMOUNT trials, and extensive SURPASS data. It is the better-characterised compound for researchers wanting established reference data.
- Studying triple receptor agonism, glucagon receptor biology, thermogenesis, or next-generation metabolic mechanisms — Retatrutide is the compound of interest. Phase 2 data is published; Phase 3 is ongoing. The mechanistic novelty of the glucagon receptor addition makes it the more research-forward choice.
- Studying maximum weight reduction outcomes or comparing compound classes — Retatrutide Phase 2 data currently shows the highest weight reduction of any compound in clinical development, making it the appropriate reference compound for comparative studies.
Both compounds are supplied in lyophilised form, reconstituted with bacteriostatic water, and have approximately weekly dosing intervals in published protocols. See the individual research guides for full reconstitution and storage protocols.
Phase 3 Outlook and Research Implications
Tirzepatide completed its Phase 3 SURMOUNT programme and received regulatory approval in the United States and multiple other jurisdictions. It is not approved for therapeutic use in Australia as of 2026, and RetaLABS supplies it for laboratory research use only.
Retatrutide is in Phase 3 TRIUMPH trials as of 2026. The programme includes trials in obesity (TRIUMPH-1), type 2 diabetes, and cardiovascular outcomes. Results from TRIUMPH-1 are anticipated in 2026–2027. If Phase 3 data confirms Phase 2 outcomes, Retatrutide would represent a step-change in the GLP-1 compound class and become the highest-efficacy incretin peptide with clinical backing.
For researchers, the practical implication is that Retatrutide currently has less published data than Tirzepatide, but the existing Phase 2 publication provides substantial mechanistic and dose-response reference material for laboratory protocols. See the Retatrutide 2026 Phase 3 Update for the latest TRIUMPH programme status.